Our vision is to produce innovative, market-leading products that will:
• Allow people to take control of their own health
• Help fight some of the world’s most deadly diseases
Sona's unique gold nanorod technology
Our products will enable a multitude of life sciences applications such as photothermal medical treatments and procedures, as well as a host of other in-vivo and in-vitro applications.
In addition, our patent-pending synthesis methodologies will allow us to also have gold nanorod products ideally suited for diagnostic test product developers.
Sona’s gold nanorods exhibit characteristics including increased sensitivity, varied colour results, tunable aspect ratios, long-term stability, facile bioconjugation, and improved shelf life.
We look forward to speaking with investors, researchers and businesses across the world about the exciting potential of our products.
The Sona Story
From an idea formed in a small laboratory in a university to a globally distributed product range, the Sona story is one of people, passion, and perseverance.
It started in 2013 when Gerrard Marangoni, professor of chemistry at St Francis Xavier University, launched a research project into gold nanorods, intrigued as to why they weren’t being used more widely.
“I quickly discovered that the presence of cytotoxins in the gold nanorods is a very important barrier to their adoption,” he said.
The presence of the cytotoxin CTAB (cetyltrimethylammonium bromide) meant gold nanorods could not be used in-vivo.
For more than a decade, manufacturers of gold nanorods had been approaching the CTAB problem by coating, removing or exchanging it and hoping for the best, but Dr. Marangoni had a simpler solution:
“Why not make gold nanorods without CTAB altogether?”
So, Dr. Marangoni tasked his research associates, Dr. Kulbir Singh and Dr. Mike McAlduff, with developing toxin-free gold nanorods that could be manufactured cost-effectively and at volume.
After four months of experimenting with different methods and chemicals, the team had its ‘eureka’ moment when it finally succeeded in developing gold nanorods free of CTAB.
That’s when Sona Nanotech was born – Sona being the Hindi word for gold.
But after that came two years of hard work to perfect the process and develop the ability to synthesize high volumes of high-quality gold nanorods.
Today, Sona has two gold nanorod products – Gemini, for diagnostic uses, and Omni, for medical applications – and is speaking with researchers in academia and industry across the world about commercializing its breakthrough development, with several collaborations already underway.
Sona’s CEO, Darren Rowles, has 15 years’ experience of working closely with gold nanoparticle technology as well as a business-focused mentality, a combination that will take the company to new heights.
In 2018 Sona merged with Stockport Exploration, listed on the Toronto Stock Exchange and relocated to new laboratory space at the Innovacorp Centre in Dartmouth.
The journey to get the company where it is today has been tough and rewarding in equal measure, but the journey ahead promises to be even more exciting.
OUR ADVANCMENTS IN GOLD NANOTECHNOLOGY HAVE THE POTENTIAL TO TRANSFORM THE DIAGNOSTIC AND MEDICAL TREATMENT MARKETS